This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD

This study has been completed.
Information provided by:
BioBalance Corporation Identifier:
First received: May 9, 2006
Last updated: January 26, 2015
Last verified: May 2006
The study is an Open Label, Prospective, Non Comparative, Pilot, clinical trial design. Patients with inadequate relief in GI symptoms associated with GERD despite PPI treatment will be screened and those who meet the inclusion and exclusion criteria will perform a glucose breath test for bacterial overgrowth . Each patient will then complete a questionnaire to record their GERD related symptoms. Each patient will then receive a daily intake of 30 mL two times daily, 30 minutes before meals for a period of 4 weeks. During the course of the trial, they will have 4 visits with the study physician to assess treatment compliance and occurrence of adverse events, and will complete periodic daily diaries to record compliance.

Condition Intervention Phase
GERD Drug: ProBactrix Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Non Comparative, Prospective Pilot Study, to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD

Further study details as provided by BioBalance Corporation:

Primary Outcome Measures:
  • improvement in one or more GI symptoms (heartburn, regurgitation, bloating, epigastric pain, abdominal pain and general well being).

Secondary Outcome Measures:
  • symptomatic response comparison between patients with a positive versus negative breath test for bacterial overgrowth
  • negative breath test for bacterial overgrowth in the patients with positive breath test at entry
  • safety

Estimated Enrollment: 60
Study Start Date: May 2006
Study Completion Date: May 2007

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age between ≥18 and ≤80, males and females.
  2. Patient administered PPI therapy for GERD.
  3. Patient suffers from any GI symptoms including GERD symptoms despite PPI therapy for at least 60 days
  4. Patient with positive or negative glucose breath test for bacterial overgrowth unless they are not able to do this secondary to diabetes. Diabetics will have a lactulose breath test
  5. Able to give informed consent
  6. Candidate will be available for the next 4 weeks

Exclusion Criteria:

1. Pregnant, breast-feeding, or not using approved methods of contraception (if of childbearing potential) 2. Unstable medical disorder 3. Patient has had E. coli strain M17 administered in the past month 4. History of major psychiatric disorder or substance abuse within the previous 2 years, including psychiatric illnesses requiring medication that may cause doubt in the validity of the signed Informed Consent form 5. Existing illness or medical condition that will prevent the patient from participating in the study (such as severe heart disease, insulin dependent diabetes, hyperactive thyroid gland, HIV positive, etc.) 6. Participation in another clinical study during the past four weeks. 7. Any use of a probiotic supplement within 30 days of the screening period (with the exception of standard food yogurt products) 8. Any use of antibiotics within 30 days of the screening/enrollment period (however, candidate may wait to initiate screening exam until 30 days have lapsed since antibiotic course was completed)

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00324532

Shaarei Zedek Medical Center
Jerusalem, Israel
Sponsors and Collaborators
BioBalance Corporation
Principal Investigator: Braverman Shaarei Zedek Medical Center
  More Information Identifier: NCT00324532     History of Changes
Other Study ID Numbers: BB 07 2005
Study First Received: May 9, 2006
Last Updated: January 26, 2015 processed this record on September 21, 2017